Fourth U.S. Site Joins VISABL-AFL Trial, Accelerating Patient Recruitment
Imricor Medical Systems has welcomed Oklahoma Heart Institute as the fourth U.S. site in its pivotal VISABL-AFL clinical trial, accelerating patient recruitment and the FDA approval pathway for its MRI-guided cardiac ablation technology.
- Oklahoma Heart Institute joins VISABL-AFL trial as fourth U.S. site
- Cardiology-owned MRI infrastructure at OHI expected to streamline trial operations
- Patient recruitment acceleration supports faster FDA approval process
- Procedures at OHI to commence in March 2026
- Dr. Edward T. Martin leads trial efforts at OHI
Expanding the Clinical Trial Footprint
Imricor Medical Systems, a pioneer in MRI-guided cardiac ablation technology, has announced a significant expansion of its VISABL-AFL clinical trial with the addition of Oklahoma Heart Institute (OHI) as the fourth U.S. enrolling site. This move is designed to accelerate patient recruitment and support the company’s ongoing efforts to secure FDA approval for its innovative ablation products.
Joining established sites such as the University of Virginia Health, Virginia Commonwealth University Health, and Johns Hopkins University, OHI brings a unique advantage with its cardiology-owned cardiac MRI facilities. This ownership model is expected to reduce capital and organisational barriers, enabling a more streamlined and efficient implementation of interventional cardiac MRI procedures.
Why Cardiology-Owned MRI Matters
The significance of cardiology ownership of MRI infrastructure cannot be overstated. It facilitates faster adoption of advanced procedures by eliminating typical hurdles related to equipment access and coordination between departments. Imricor’s management sees this as a strategic pathway to accelerate market adoption while lowering hospital capital expenditure, a critical factor in the broader acceptance of MRI-guided ablation techniques.
Procedures at OHI are slated to begin in March 2026 under the leadership of Dr. Edward T. Martin, a globally recognised expert in cardiovascular magnetic resonance imaging. Dr. Martin’s involvement adds considerable credibility and expertise to the trial, reflecting the cutting-edge nature of the technology and its potential to improve ablation success rates.
Implications for FDA Approval and Market Momentum
The addition of OHI is expected to not only speed up patient enrolment in the U.S. but also allow European trial sites to complete their participation sooner, enabling them to return to revenue-generating clinical activities. This dual benefit could enhance the overall efficiency of the VISABL-AFL trial and bring Imricor closer to achieving FDA approval, a critical milestone for commercialisation in the lucrative U.S. market.
Steve Wedan, Imricor’s Chair and CEO, emphasised the strategic value of OHI’s cardiology-led model, highlighting how it reduces organisational complexity and fosters innovation. The company’s vision is clear, to transform cardiac ablation by leveraging MRI’s superior imaging capabilities, ultimately improving patient outcomes and procedural safety.
Looking Ahead
As Imricor continues to build momentum with its VISABL-AFL trial, the integration of high-calibre sites like Oklahoma Heart Institute signals growing confidence in the technology’s potential. The coming months will be critical as patient recruitment ramps up and the trial progresses toward regulatory milestones.
Bottom Line?
Oklahoma Heart Institute’s entry into the VISABL-AFL trial marks a pivotal step in Imricor’s journey toward FDA approval and broader clinical adoption.
Questions in the middle?
- How quickly will patient recruitment accelerate with OHI onboard?
- What impact will cardiology-owned MRI infrastructure have on trial outcomes?
- When can investors expect updates on FDA approval progress?
